{
    "Trade/Device Name(s)": [
        "i-STAT G cartridge with the i-STAT 1 System",
        "i-STAT G cartridge on the i-STAT 1 System"
    ],
    "Submitter Information": "Abbott Point of Care Inc.",
    "510(k) Number": "K223755",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210958",
        "K183678"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGA"
    ],
    "Summary Letter Date": "September 11, 2023",
    "Summary Letter Received Date": "August 9, 2023",
    "Submission Date": "August 8, 2023",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Arterial whole blood",
        "Venous whole blood",
        "Capillary whole blood"
    ],
    "Specimen Container(s)": [
        "Without anticoagulant",
        "With balanced heparin",
        "Lithium heparin",
        "K2 EDTA",
        "K3 EDTA"
    ],
    "Instrument(s)/Platform(s)": [
        "i-STAT 1 analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric measurement using glucose oxidase"
    ],
    "Methodologies": [
        "Electrochemical detection"
    ],
    "Submission Type(s)": [
        "Cartridge",
        "Analyzer",
        "System",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for i-STAT G cartridge with the i-STAT 1 System for point-of-care glucose quantification in whole blood using amperometric measurement technology",
    "Indications for Use Summary": "Intended for in vitro quantification of glucose in arterial, venous, or capillary whole blood in point of care or clinical laboratory settings for diagnosis, monitoring, and treatment of carbohydrate metabolism disorders such as diabetes mellitus, neonatal hypoglycemia, idiopathic hypoglycemia, and pancreatic islet cell carcinoma",
    "fda_folder": "Clinical Chemistry"
}